Alan S. Roemer
Chairman presso IN8BIO, INC.
Patrimonio netto: 186 969 $ in data 31/03/2024
Profilo
Alan S.
Roemer is currently the Chairman at IN8bio, Inc. and UTILITY therapeutics Ltd.
He is also a Director at DC Brau Brewing LLC, Envisagenics, Inc., and Bit Bio Ltd.
Additionally, he serves as a Trustee at Helene Fuld College of Nursing.
Previously, he held positions such as Managing Director at Trout Capital LLC and The Trout Group LLC, Director at Sompharmaceuticals SA, Chief Financial Officer & Treasurer at Azelon Pharmaceuticals, Inc., and Vice President-Investor Relations at Pharmasset, Inc. He has also worked as a Consultant at Deloitte Consulting LLP and Booz Allen Hamilton International (U.K.) Ltd.
Furthermore, he served as the Chief Financial & Accounting Officer at Sio Gene Therapies, Inc. and Chief Financial Officer at Axovant Sciences, Inc. He was a Senior Vice President at Roivant Sciences, Inc. Mr. Roemer has an undergraduate degree from Georgetown University, an MBA from Goizueta Business School-Emory, and a graduate degree from Rollins School of Public Health.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
IN8BIO, INC.
0.37% | 13/12/2023 | 158 448 ( 0.37% ) | 186 969 $ | 31/03/2024 |
NEXIMMUNE, INC.
-.--% | 22/11/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Alan S. Roemer
| Società | Posizione | Inizio |
|---|---|---|
| NEXIMMUNE, INC. | Director/Board Member | 16/12/2019 |
| IN8BIO, INC. | Chairman | 01/09/2020 |
UTILITY therapeutics Ltd.
 UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Chairman | 01/03/2020 |
Bit Bio Ltd.
 Bit Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Bit Bio Ltd. engages in research and experimental development on natural sciences and engineering. Its products are human-induced skeletal myocytes and glutamatergic neurons. The company was founded by Mark Kotter in 2016 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - |
| Helene Fuld College of Nursing | Director/Board Member | 01/06/2014 |
DC Brau Brewing LLC
 DC Brau Brewing LLC Beverages: AlcoholicConsumer Non-Durables DC Brau Brewing LLC manufactures and distributes beer. The company was founded by Jeffrey Hancock and Brandon Skall in 2009 and is headquartered in Washington, DC. | Director/Board Member | - |
Envisagenics, Inc.
 Envisagenics, Inc. BiotechnologyHealth Technology Envisagenics, Inc. engages in developing of artificial intelligence platform for discovering drugs. The company was founded by Maria Luisa Pineda and Martin Akerman and is headquartered in New York, NY. | Director/Board Member | - |
Precedenti posizioni note di Alan S. Roemer
| Società | Posizione | Fine |
|---|---|---|
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/08/2019 |
| Sompharmaceuticals SA | Director/Board Member | 01/05/2016 |
| ░░░ ░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Alan S. Roemer
| Georgetown University | Undergraduate Degree |
| Goizueta Business School-Emory | Masters Business Admin |
| Rollins School of Public Health | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Finance |
| NEXIMMUNE, INC. | Health Technology |
| Aziende private | 15 |
|---|---|
Azelon Pharmaceuticals, Inc.
 Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | Health Technology |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
DC Brau Brewing LLC
DC Brau Brewing LLC Beverages: AlcoholicConsumer Non-Durables DC Brau Brewing LLC manufactures and distributes beer. The company was founded by Jeffrey Hancock and Brandon Skall in 2009 and is headquartered in Washington, DC. | Consumer Non-Durables |
Deloitte Consulting LLP
 Deloitte Consulting LLP Miscellaneous Commercial ServicesCommercial Services Deloitte Consulting LLP provides business consulting services. It offers services related to public finance, public sector management, health and social protection, information technology, financial sector, and trade and investment. The company was founded in 1996 and is headquartered in New York, NY. | Commercial Services |
Trout Capital LLC
 Trout Capital LLC Investment Banks/BrokersFinance The Trout Group LLC is an investor relations and strategic advisory firm exclusively serving the life sciences industry. Since 1995, they have been providing companies in the sector with access to the U.S. institutional investment community. Trout is headquartered in New York and has additional offices in Waltham, Massachusetts and San Francisco. | Finance |
Booz Allen Hamilton International (U.K.) Ltd.
 Booz Allen Hamilton International (U.K.) Ltd. Miscellaneous Commercial ServicesCommercial Services Booz Allen & Hamilton International provides management and technology consulting services. The company provides services to international corporations and governments around the world. It was founded in 1914 and is located in McLean, VA. | Commercial Services |
The Trout Group LLC
 The Trout Group LLC Financial ConglomeratesFinance The Trout Group LLC operates as an investor relations and strategic advisory firm servicing the life science industry. It offers investor relations strategy, targeting and outreach, market intelligence, investor relation event planning and execution, investor relations materials, and corporate communications services. The company was founded by Jonathan B. Fassberg in 2004 and is headquartered in New York, NY. | Finance |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Axovant Sciences, Inc.
 Axovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sio Gene Therapies, Inc., Axovant Sciences, Inc. is a private company that manufactures and distributes pharmaceutical products. The company is based in New York, NY. | Health Technology |
Envisagenics, Inc.
Envisagenics, Inc. BiotechnologyHealth Technology Envisagenics, Inc. engages in developing of artificial intelligence platform for discovering drugs. The company was founded by Maria Luisa Pineda and Martin Akerman and is headquartered in New York, NY. | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
| IN8bio, Inc. | |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Health Technology |
Bit Bio Ltd.
Bit Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Bit Bio Ltd. engages in research and experimental development on natural sciences and engineering. Its products are human-induced skeletal myocytes and glutamatergic neurons. The company was founded by Mark Kotter in 2016 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
| Sompharmaceuticals SA |
- Borsa valori
- Insiders
- Alan S. Roemer
